Sign in
Taking peoplePhase 3

Comparing two rituximab schedules for adults with relapsing steroid-sensitive nephrotic syndrome

Compares two rituximab schedules for keeping nephrotic syndrome from returning in adults.

Key facts

Who runs it
Medical University Of Lodz
Where
Poland12 sites in 1 countryChoose a country to see its sites
Registry title
BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults. (B cell Depletion Therapy to Improve Outcomes of Relapsing STERoid-sensitive Podocytopathies in Adults – BOOSTER trial)
Status
Recruiting
Phase
Phase 3
People taking part
70 people, planned
Started
28 Apr 2025
Expected to end
30 Nov 2029
Type of study
Interventional
Record updated
29 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with relapsing nephrotic syndrome caused by podocytopathy (MCD or FSGS) that responds to steroids. It compares two rituximab maintenance schedules.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Primary (immune-mediated) podocytopathy, usually MCD or FSGS on biopsy. At least 1 relapse in the past, the latest within 2 years before joining. The latest relapse came during immune-suppressing treatment or within 6 months after it stopped. At joining, the disease must be at least in partial remission, with proteinuria < 1.0 g/day (or uPCR <1000 mg/g).
Earlier treatment
The disease must have responded well to steroids (GCS) and/or other immune-suppressing drugs within 16 weeks. People must be on immune-suppressing treatment to keep remission, for at least 2 weeks after reaching remission. No cyclophosphamide in the 6 months and no rituximab in the 18 months before joining.
Biomarker or test result
Proteinuria < 1.0 g/day (or uPCR <1000 mg/g) at joining. eGFR must be 45 ml/min/1.73m2 or more. Negative tests for HIV, HBs antigen and active HCV (HCV RNA).

Main reasons for not taking part

  • A likely secondary cause of the kidney disease, such as certain drugs, cancer-related syndrome or podocyte protein mutations
  • Reasons rituximab cannot be given, such as allergy, severe active infection, severe immune weakness, NYHA class IV heart failure, or a live vaccine within 4 weeks
  • Pregnancy, breastfeeding, or refusing effective birth control during the study
  • eGFR less than 45 ml/min/1.73m2
  • Active cancer or cancer in the last 5 years

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Informed consent to participate in the study
  • Age of at least 18 years
  • Diagnosis of podocytopathy of the most likely primary (immune-mediated) nature, meeting all of the following criteria: a. Histopathological diagnosis of MCD (Minimal Change Disease) or FSGS (Focal Segmental Glomerulosclerosis)*; b. A good response to immunosuppressive therapy - defined as complete remission of nephrotic syndrome or partial remission with proteinuria <1.0 g/day (or uPCR <1000 mg/g) within 16 weeks of treatment with GCS and/or GCS-sparing immunosuppressive drug(s); c. Excluded secondary causes of nephrotic syndrome. *It is acceptable to include a patient without or with a non-diagnostic biopsy result as long as criteria 3b and 3c are met and the disease course is typical of podocytopathy and the differential diagnosis does not support another diagnosis. Each case should be considered individually, in consultation with the Coordinating Investigator
  • A relapsing course of disease that meets all of the following criteria (a-c): a. At least 1 relapse of nephrotic syndrome in the history; b. Most recent relapse within 2 years prior to study enrollment of: • Nephrotic syndrome, OR • Subnephrotic proteinuria (>1.0 g to 3.5 g/day), provided that immunosuppressive therapy was reinitiated or intensified; c. The most recent relapse occurred during immunosuppressive therapy or within 6 months of its discontinuation
  • Ongoing immunosuppressive treatment to maintain remission after the last relapse lasting min. 2 weeks from achieving partial or complete remission
  • At the time of inclusion in the study, at least partial remission of disease with proteinuria < 1.0 g/day (or uPCR <1000 mg/g) achieved with treatment with glucocorticoids and/or glucocorticoids-sparing immunosuppressant/immunosuppressants

Who cannot take part

  • Treatment with cyclophosphamide within 6 months prior to study inclusion
  • Treatment with rituximab within 18 months prior to study inclusion
  • Probable or certain secondary cause of podocytopathy, including, but not limited to, chronic use of medications with a confirmed association with MCD (Minimal Change Disease) (e.g., lithium salts, interferon, non-steroidal anti-inflammatory drugs), paraneoplastic syndrome, podocyte protein mutations
  • A positive result on any of the following virology tests: a. Presence of anti-HIV antibodies; b. Presence of anti-HCV antibodies** and HCV RNA viremia; c. Presence of HBs antigen. If anti-HCV antibodies are found, the patient may be eligible for the study provided that HCV RNA viremia is absent
  • Active neoplastic disease or history of neoplastic disease in the last 5 years
  • Any other abnormality or disease not described above that excludes the patient from the study based on the Investigator's assessment
  • Presence of any of the contraindications to the administration of rituximab (according to the SmPC): a. Hypersensitivity to the active substance or excipients; b. Hypersensitivity to mouse proteins; c. Active infection with a severe course; d. Severe immunodeficiency*; e. Pregnancy, breastfeeding, or refusal to use effective pregnancy prevention methods during the study (applies to women); f. Severe heart failure (NYHA class IV) or severe uncontrolled heart disease. g. Post-vaccination status with a live vaccine within 4 weeks prior to study inclusion. * Immunoglobulin G deficiency secondary to nephrotic syndrome, as well as immunoglobulin G deficiency with serum IgG levels >250 g/L without a history of severe infectious complications, should not be considered as an absolute exclusion criterion. Each case should be considered individually
  • Glomerular filtration rate - eGFR less than 45 ml/min/1.73m2 according to the CKD-EPI 2021 formula

This trial is currently available in Poland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To compare the efficacy of two Rituximab treatment regimens in terms of time to nephrotic syndrome recurrence (non-inferiority hypothesis).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults.
Plain-language title
Comparing two rituximab schedules for adults with relapsing steroid-sensitive nephrotic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
29 July 2026